8-K current report · filed Aug 21, 2026

Gossamer Bio, Inc. (GOSS) 8-K Current Report: August 21, 2026

Item EX-99.1Item 5.03Item 3.02Item 7.01Item 1.01GOSS overview

Short answer

Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on August 21, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 1.01 (Entry into a Material Definitive Agreement). Private placement targets $25.0M initially and $125.0M at NDA acceptance, funding seralutinib development and potential commercialization.

Gossamer Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Private placement targets $25.0M initially and $125.0M at NDA acceptance, funding seralutinib development and potential commercialization
  • Second closing requires FDA acceptance of the seralutinib PAH NDA during 2026, tying additional capital to a regulatory milestone
  • FDA Approval Warrants could provide approximately $100.0M additional proceeds if seralutinib receives FDA approval
  • Securities convert into substantial common stock at $0.14, approximately $0.187, or a five-day VWAP, creating significant dilution risk
  • Stockholder approval is required, with existing investors supporting the issuance and preferred holders receiving a 4x liquidation preference before approval

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Planned Delaware charter amendments creating Series A-1, A-2 and A-3 convertible preferred stock
  • Series A-1 designation targeted before the Initial Closing
  • Series A-2 and A-3 designations contingent on missing stockholder approval before the Second Closing
  • Preferred-stock rights and conversion terms governed by the filed certificates and Item 1.01 terms

Item 7.01 · Regulation FD Disclosure

  • Press release announces Gossamer Bio’s entry into a Purchase Agreement
  • Purchase Agreement represents a potentially material transaction requiring investor review of Exhibit 99.1 terms
  • Transaction details, consideration and strategic impact are contained in the attached press release

Item EX-99.1 · Exhibit EX-99.1

  • Up to $250M financing funds seralutinib development through potential FDA approval, reducing near-term financing risk
  • $25M initial closing expected August 24, 2026, plus $125M committed upon FDA acceptance of the PAH NDA
  • Additional warrants could generate up to $100M upon FDA approval at a $0.187 exercise price
  • Funding depends on regulatory milestones and stockholder approval, creating execution and dilution risks
  • Proceeds expected to fund operations into 2028, including PAH and PH-ILD development and commercialization preparation

Other items in this filing:

  • Item 3.02: Unregistered Sales of Equity Securities

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Gossamer Bio, Inc. 8-K filings

Get the next GOSS 8-K as it lands

Follow GOSS for push alerts, or ask the research agent what this filing means.